Ghatnekar O, Hjalte F, Taylor M. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application. AO [Internet]. 2010 Aug. 1 [cited 2025 Feb. 21];49(6):851-8. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/32708